TGFBR2 and acute myeloid leukemia: The TGF-β receptor 2 (TGFβR2) gene was deleted using CRISPR/Cas9 technology in primary human NK cells, rendering them immune to this immunosuppressive growth factor without losing their efficacy against AML (174).